Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • PF-5212377: Phase II discontinued

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: PF-5212377, WYE-103760, PF-05212377 (formerly SAM-760) Business: Neurology Molecular target: Serotonin (5-HT6) receptor Description: Antagonist of serotonin (5-HT6) …

    Published on 2/8/2016
  • PUR0200: Phase I started

    Pulmatrix Inc. (NASDAQ:PULM), Lexington, Mass. Product: PUR0200 Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled dry powder formulation of tiotropium, a long-acting muscarinic antagonist (…

    Published on 2/8/2016
  • Ruconest conestat alfa: Completed Phase II enrollment

    Pharming Group N.V. (Euronext:PHARM), Leiden, the Netherlands Product: Ruconest conestat alfa (rhC1INH) Business: Inflammation Molecular target: Complement 1 (C1) esterase Description: Recombinant human complement 1 (C1…

    Published on 2/8/2016
  • Simdax levosimendan: Phase III ongoing

    Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Tenax Therapeutics Inc. (NASDAQ:TENX), Morrisville, N.C. Product: Simdax levosimendan Business: Cardiovascular Molecular target: Potassium channel Description: Calcium …

    Published on 2/8/2016
  • SIRPalphaFc: Phase I started

    Trillium Therapeutics Inc. (TSX:TR; NASDAQ:TRIL), Toronto, Ontario Product: SIRPalphaFc (TTI-621) Business: Cancer Molecular target: CD47 Description: Fusion protein comprising the CD47-binding domain of signal …

    Published on 2/8/2016
  • Verubecestat: Completed Phase II/III enrollment

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Verubecestat (SCH 900931, MK-8931) Business: Neurology Molecular target: Beta-site APP-cleaving enzyme 1 (BACE1) Description: Beta-site APP-cleaving enzyme 1 (BACE1…

    Published on 2/8/2016
  • VRC01LS: Phase I started

    Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. National Institutes of Health, Bethesda, Md. Product: VRC01LS, VRC-HIVMAB080-00-AB Business: Infectious Molecular target: CD4 Description: Humanized mAb targeting the CD4 …

    Published on 2/8/2016
  • ZPL-389: Phase IIa started

    Ziarco Group Ltd., Canterbury, U.K. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: ZPL-389, ZPL-3893787 (formerly PF-03893787) Business: Autoimmune Molecular target: Histamine H4 receptor (HRH4) (H4) Description: …

    Published on 2/8/2016
  • 5B1 antibody: Phase I start

    MabVax Therapeutics Holdings Inc. (OTCQB:MBVX), San Diego, Calif. Product: 5B1 antibody, HuMab-5B1 (MVT-5873) Business: Cancer Molecular target: Undisclosed Description: Human IgG1 antibody Indication: Treat metastatic …

    Published on 2/1/2016
  • ADU-741: Phase I started

    Aduro Biotech Inc. (NASDAQ:ADRO), Berkeley, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ADU-741, JNJ-64041809 Business: Cancer Molecular target: NA Description: Live-attenuated, double-deleted …

    Published on 2/1/2016
  • AK001: Phase I ongoing

    Allakos Inc., San Carlos, Calif. Product: AK001 Business: Inflammation Molecular target: Undisclosed Description: Antibody targeting an inhibitory receptor on mast cells and eosinophils Indication: Treat atopic disease …

    Published on 2/1/2016
  • Anetumab ravtansine: Phase II started

    MorphoSys AG (Xetra:MOR), Martinsried, Germany Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Anetumab ravtansine (BAY 94-9343) Business: Cancer Molecular target: Mesothelin Description: Human HuCAL-based antibody-…

    Published on 2/1/2016
  • ARC-520: Phase IIb started

    Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Product: ARC-520 Business: Infectious Molecular target: NA Description: Short interfering RNAs targeting 2 regions of the HBV genome conjugated to N-…

    Published on 2/1/2016
  • BeiGene-290: Phase I started

    BeiGene Ltd., Beijing, China Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: BeiGene-290, BGB-290 Business: Cancer Molecular target: Poly(ADP-ribose) polymerase-1 (PARP-1); Poly(ADP-ribose) polymerase-2 (PARP-2) …

    Published on 2/1/2016
  • BGB-A317: Phase I started

    BeiGene Ltd., Beijing, China Product: BGB-A317 Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: Humanized anti-PD-1 mAb Indication: Treat advanced solid tumors Endpoint: …

    Published on 2/1/2016
  • BIA 10-2474: Phase I halted

    Bial-Portela & Ca. S.A., S. Mamede do Coronado, Portugal Product: BIA 10-2474 Business: Neurology Molecular target: Fatty acid amide hydrolase (FAAH) Description: Fatty acid amide hydrolase (FAAH) inhibitor Indication: …

    Published on 2/1/2016
  • Bryostatin-1: Phase IIb started

    Neurotrope Inc. (OTCQB:NTRP), Newark, N.J. Product: Bryostatin-1 Business: Neurology Molecular target: Protein kinase C (PKC) epsilon (PKCE) Description: Protein kinase C (PKC) epsilon (PKCE) activator Indication: Treat…

    Published on 2/1/2016
  • CBLB612: Phase II started

    Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Product: CBLB612 Business: Hematology Molecular target: Toll-like receptor 2 (TLR2); Toll-like receptor 6 (TLR6) Description: Synthetic lipopeptide derived from …

    Published on 2/1/2016
  • CGF166: Phase I/II suspended enrollment

    GenVec Inc. (NASDAQ:GNVC), Gaithersburg, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: CGF166 Business: Other Molecular target: Atonal homolog 1 (ATOH1) (HATH1) Description: Recombinant adenovirus 5…

    Published on 2/1/2016
  • DTX101: Phase I/II started

    RegenxBio Inc. (NASDAQ:RGNX), Washington, D.C. Dimension Therapeutics Inc. (NASDAQ:DMTX), Cambridge, Mass. Product: DTX101 Business: Hematology Molecular target: Factor IX Description: Recombinant adeno-associated virus…

    Published on 2/1/2016
  • eFT508: Phase I/II started

    Effector Therapeutics Inc., San Diego, Calif. Product: eFT508 Business: Cancer Molecular target: MAP kinase interacting serine-threonine kinase 1 (MKNK1) (MNK1); MAP kinase interacting serine-threonine kinase 2 (MKNK2)…

    Published on 2/1/2016
  • EGP-437: Phase III started

    EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG), Waltham, Mass. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: EGP-437 Business: Ophthalmic Molecular target: NA Description: …

    Published on 2/1/2016
  • EV06: Completed Phase I/II enrollment

    Encore Vision Inc., Fort Worth, Texas Product: EV06 Business: Ophthalmic Molecular target: NA Description: 1.5% lipoic acid choline ester, which breaks down into lipoic acid and choline Indication: Treat presbyopia …

    Published on 2/1/2016
  • FG-3019: Phase II started

    FibroGen Inc. (NASDAQ:FGEN), San Francisco, Calif. Product: FG-3019 Business: Musculoskeletal Molecular target: Connective tissue growth factor (CTGF) Description: Human mAb against connective tissue growth factor (CTGF…

    Published on 2/1/2016
  • GLPG2222: Phase I started

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: GLPG2222 Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator (CFTR) …

    Published on 2/1/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993